TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33756376

Group type: EXPERIMENTAL
Intervention: Integrated Exposure Therapy (I-PE)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Integrated Coping Skills Therapy (I-CS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 119
Study: 34896126

Group type: EXPERIMENTAL
Intervention: Topical Chlorhexidine 0.2%
Number of subjects: 354

Group type: COMPARATOR
Intervention: Topical Natamycin 5%
Number of subjects: 354
Study: 34006536

Group type: EXPERIMENTAL
Intervention: Supported home exercise programme (initially one face-to-face session, then managed remotely for 6 weeks)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Face-to-face physiotherapy (course of physiotherapy as typically provided in Sydney government hospitals)
Number of subjects: 210
Study: 32817131

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (n=261)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo plus Best Supportive Care (BSC)
Number of subjects: 800
Study: 32668874

Group type: EXPERIMENTAL
Intervention: V-shaped incision (VI) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blair incision (BI) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hairline N-shaped incision (NI) group
Number of subjects: 60
Study: 36387350

Group type: EXPERIMENTAL
Intervention: Descurainia sophia (DS) for six weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 53
Study: 36704072

Group type: EXPERIMENTAL
Intervention: Telehealth transdiagnostic CBT (12 sessions)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 12
Study: 33380183

Group type: EXPERIMENTAL
Intervention: CR-FB design
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: PS-FB design
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CR-RP design
Number of subjects: 68
Study: 32627722

Group type: EXPERIMENTAL
Intervention: Prioritized areas of research related to life after stroke
Number of subjects: 589

Group type: COMPARATOR
Intervention: Gender differences in prioritization
Number of subjects: 589

Group type: COMPARATOR
Intervention: Age differences in prioritization
Number of subjects: 589
Study: 35365369

Group type: EXPERIMENTAL
Intervention: 2-hour interprofessional SDM training (didactic and interactive training using video examples)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Wait-list control (CG)
Number of subjects: 134
Study: 35308782

Group type: EXPERIMENTAL
Intervention: Nomograms for predicting overall survival (OS)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Nomograms for predicting cancer-specific survival (CSS)
Number of subjects: 893

Group type: COMPARATOR
Intervention: Nomograms compared to AJCC staging system
Number of subjects: 893
Study: 35141977

Group type: EXPERIMENTAL
Intervention: Integra® matrix
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pelnac® matrix
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Matriderm® matrix
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control Group (without dermal matrix)
Number of subjects: 39
Study: 34015244

Group type: EXPERIMENTAL
Intervention: SGS-742
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 32782077

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combination of EMLA cream and massage
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control
Number of subjects: 140
Study: 34921836

Group type: EXPERIMENTAL
Intervention: High intensity of effort resistance training (HIT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Routine care (CON)
Number of subjects: 57
Study: 34207661

Group type: EXPERIMENTAL
Intervention: Intervention to reduce sitting time
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 35175971

Group type: EXPERIMENTAL
Intervention: Positively Smoke Free on the Web (PSFW+); N = 255
Number of subjects: 506

Group type: COMPARATOR
Intervention: American Heart Association Getting Healthy (control); N = 251
Number of subjects: 506
Study: 33706032

Group type: EXPERIMENTAL
Intervention: TB treatment support tools (TB‐TSTs)
Number of subjects: 42
Study: 35617330

Group type: EXPERIMENTAL
Intervention: HSCP team intervention
Number of subjects: 26
Study: 34222086

Group type: EXPERIMENTAL
Intervention: Methylethylpiridinol addition to therapy
Number of subjects: 0
Study: 32645767

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ANH
Number of subjects: 24
Study: 33032893

Group type: EXPERIMENTAL
Intervention: Inpatient initiation of sacubitril/valsartan
Number of subjects: 840

Group type: COMPARATOR
Intervention: Outpatient initiation of sacubitril/valsartan
Number of subjects: 840
Study: 33626929

Group type: EXPERIMENTAL
Intervention: Systemic therapy and local therapy (radiation, surgery, thermal ablation)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 102
Study: 33213815

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 35635687

Group type: EXPERIMENTAL
Intervention: Lower-sodium oxybate (LXB)
Number of subjects: 4
Study: 32732442

Group type: EXPERIMENTAL
Intervention: Fixed-loop group (30 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adjustable-loop group (30 patients)
Number of subjects: 60
Study: 35251416

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 ml infiltration injection)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 ml infiltration injection)
Number of subjects: 80
Study: 33710131

Group type: EXPERIMENTAL
Intervention: ICBN Preservation
Number of subjects: 48

Group type: COMPARATOR
Intervention: ICBN Sacrifice
Number of subjects: 48
Study: 32266366

Group type: EXPERIMENTAL
Intervention: Franchised gyms
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gyms without swimming pools
Number of subjects: 90
Study: 35433565

Group type: EXPERIMENTAL
Intervention: Health Education Module on Hand, Food, and Mouth Diseases
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study: 34281377

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Control arm (intravenous alteplase)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 443
Study: 34907038

Group type: EXPERIMENTAL
Intervention: Sociological variety indicators (e.g., crowding, movement, livelihoods, recreational activity)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Socially open communities with poor ventilation (e.g., watching video shows)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Outdoor farming and/or fishing in communities with lower transmission measures
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adjustments to socio-spatial aspects (e.g., increasing ventilation on transport)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Integration of community level typologies with genome sequencing techniques
Number of subjects: 15
Study: 33338662

Group type: EXPERIMENTAL
Intervention: Nebulized sodium nitrite (15 mg twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35512458

Group type: EXPERIMENTAL
Intervention: BGF 320/14.4/10 μg
Number of subjects: 8509

Group type: EXPERIMENTAL
Intervention: BGF 160/14.4/10 μg
Number of subjects: 8509

Group type: COMPARATOR
Intervention: GFF 14.4/10 μg
Number of subjects: 8509

Group type: COMPARATOR
Intervention: BFF 320/10 μg
Number of subjects: 8509
Study: 33268020

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam (LZP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35231098

Group type: EXPERIMENTAL
Intervention: X‐CircuiT (46 min/session, three supervised sessions/week for 3 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (1-time advice on physical activity without supervised exercise)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: X‐CircuiT
Number of subjects: 48

Group type: COMPARATOR
Intervention: X‐CircuiT vs Control
Number of subjects: 48
Study: 32563277

Group type: EXPERIMENTAL
Intervention: Tepotinib plus gefitinib
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 55
Study: 34963006

Group type: EXPERIMENTAL
Intervention: Adper Single Bond 2 (SB)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ambar (AM)
Number of subjects: 35
Study: 33950583

Group type: EXPERIMENTAL
Intervention: Intervention (WHO STOPS Childhood Obesity)
Number of subjects: 1792
Study: 35442219

Group type: EXPERIMENTAL
Intervention: Healer-delivered HIV testing
Number of subjects: 107
Study: 33270487

Group type: EXPERIMENTAL
Intervention: Men-AC vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lanzhou-AC vaccine (Control)
Number of subjects: 0
Study: 33919758

Group type: EXPERIMENTAL
Intervention: INTER-ACT lifestyle intervention (smartphone application + 4 face-to-face coaching sessions between 6 weeks and 6 months postpartum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36004504

Group type: EXPERIMENTAL
Intervention: Intradermal BTX‐A injection (50‐65 U)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intradermal normal saline (NS) injection
Number of subjects: 49
Study: 36279088

Group type: EXPERIMENTAL
Intervention: Prophylactic drain placement
Number of subjects: 108

Group type: COMPARATOR
Intervention: No drain placement
Number of subjects: 108
Study: 33022345

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 52
Study: 35249225

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT; 70% maximal heart rate, 45 min; n=17)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT; 90% maximal heart rate, 10×1 min; n=19)
Number of subjects: 36
Study: 33838349

Group type: EXPERIMENTAL
Intervention: Lubiprostone 12 μg BID
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 μg BID
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study: 32245464

Group type: EXPERIMENTAL
Intervention: Palovarotene 20 mg/day for 4 weeks, then 10 mg/day for 8 weeks after left hip fracture surgery.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Palovarotene 20 mg/day started at fracture occurrence, continued for 4 weeks, then reduced to 10 mg/day for 8 weeks after right hip fracture surgery.
Number of subjects: 1
Study: 35898773

Group type: EXPERIMENTAL
Intervention: Compound Danshen injection combined with magnesium sulfate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Magnesium sulfate (control)
Number of subjects: 60
Study: 33904664

Group type: EXPERIMENTAL
Intervention: 500 ml of Mountain Dew® (caffeinated soft drink sweetened with high-fructose corn syrup)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 500 ml of tap water (H2O)
Number of subjects: 14
Study: 32452969

Group type: EXPERIMENTAL
Intervention: Male condom with placebo silicone vaginal ring
Number of subjects: 70

Group type: COMPARATOR
Intervention: Male condom without placebo silicone vaginal ring
Number of subjects: 70
Study: 36378553

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1 g/day; 1.2:1 ratio of eicosapentaenoic to docosahexaenoic acid)
Number of subjects: 25871
Study: 34116708

Group type: EXPERIMENTAL
Intervention: On-site pharmacists integrated into healthcare teams for 2 to 2.5 days per week for 12 months
Number of subjects: 1188

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: On-site pharmacists integrated into healthcare teams
Number of subjects: 1188
Study: 32956433

Group type: EXPERIMENTAL
Intervention: Short-term water storage
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thermal degradation with autoclaving
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chemical degradation with hydrochloric acid
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chemical degradation with citric acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study: 34951021

Group type: EXPERIMENTAL
Intervention: Mycobacterium indicus pranii (MIP)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Best standard treatment (BST)
Number of subjects: 315
Study: 34795952

Group type: EXPERIMENTAL
Intervention: Mirogabalin (clinical dose) added to conventional therapy (non-steroidal anti-inflammatory drugs and/or acetaminophen) for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (non-steroidal anti-inflammatory drugs and/or acetaminophen) without mirogabalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (with and without mirogabalin)
Number of subjects: 0
Study: 32725772

Group type: EXPERIMENTAL
Intervention: Cisplatin dose per kilogram lean body mass (LBM) in the first course
Number of subjects: 157

Group type: COMPARATOR
Intervention: Standard treatment (concurrent platinum–etoposide chemotherapy and thoracic radiotherapy)
Number of subjects: 157
Study: 34906334

Group type: EXPERIMENTAL
Intervention: Ponatinib (30 mg daily) with FLAG-IDA (fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ponatinib (30 mg daily) with FLAG-IDA
Number of subjects: 17
Study: 35002919

Group type: EXPERIMENTAL
Intervention: Cognitive telerehabilitation through HomeCoRe
Number of subjects: 40

Group type: COMPARATOR
Intervention: In-person cognitive intervention through CoRe
Number of subjects: 40
Study: 35084987

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (3 cycles of gemcitabine + 36 Gy radiotherapy in 15 fractions) followed by surgery and 4 cycles of adjuvant gemcitabine
Number of subjects: 246

Group type: COMPARATOR
Intervention: Upfront surgery followed by 6 cycles of adjuvant gemcitabine
Number of subjects: 246
Study: 33063439

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 527
Study: 33091752

Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) supplementation at 150 mg/kg/d for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard isocaloric and isonitrogenic breeder diet (Control, LC-0)
Number of subjects: 24
Study: 35569569

Group type: EXPERIMENTAL
Intervention: Oral motor intervention combined with non-nutritive sucking
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-nutritive sucking intervention alone
Number of subjects: 60
Study: 34018981

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study: 32385016

Group type: EXPERIMENTAL
Intervention: Psychological nursing alongside conventional nursing care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional nursing care
Number of subjects: 60
Study: 36147329

Group type: EXPERIMENTAL
Intervention: BRII-196 (up to 3000 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: BRII-198 (up to 3000 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of BRII-196 and BRII-198 (up to 1500/1500 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: BRII-196 and BRII-198
Number of subjects: 44
Study: 33356011

Group type: EXPERIMENTAL
Intervention: Prazosin (1 mg/day for 1 week)
Number of subjects: 51
Study: 34856379

Group type: EXPERIMENTAL
Intervention: LUS-guided dry-weight reduction (n = 35)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard-of-care treatment (n = 36)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: LUS-guided dry-weight reduction
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard-of-care treatment
Number of subjects: 71
Study: 32167568

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 73
Study: 33384915

Group type: EXPERIMENTAL
Intervention: Preventure intervention delivered by school staff (two 90-minute group sessions incorporating cognitive-behavioural therapy and motivational interviewing)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual Health Education curriculum (control condition)
Number of subjects: 12
Study: 32179568

Group type: EXPERIMENTAL
Intervention: oat-RUTF
Number of subjects: 1406

Group type: COMPARATOR
Intervention: s-RUTF
Number of subjects: 1406
Study: 34119421

Group type: EXPERIMENTAL
Intervention: 10 g flaxseed supplementation
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 30 g flaxseed supplementation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 34906295

Group type: EXPERIMENTAL
Intervention: PCSK9 knockdown (si-PCSK9)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control small interfering RNA (si-NC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EndoMT group (no treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blank group (no treatment)
Number of subjects: 0
Study: 33792496

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) in addition to conventional physiotherapy rehabilitation program (CPRP) for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physiotherapy rehabilitation program (CPRP) that included balance exercises
Number of subjects: 30
Study: 34565678

Group type: EXPERIMENTAL
Intervention: Bedinvetmab (0.5–1.0 mg kg–1, n = 141)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo (saline, n = 146)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Bedinvetmab (0.5–1.0 mg kg–1)
Number of subjects: 287
Study: 32455620

Group type: EXPERIMENTAL
Intervention: DieTBra
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DieTBra + EVOO (52 mL/day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: EVOO (52 mL/day)
Number of subjects: 111
Study: 36382849

Group type: EXPERIMENTAL
Intervention: Pevonedistat 25 mg/m2
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pevonedistat 50 mg/m2
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pevonedistat
Number of subjects: 44
Study: 32975708

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus epirubicin (NE)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Paclitaxel plus epirubicin (PE)
Number of subjects: 91
Study: 32613209

Group type: EXPERIMENTAL
Intervention: Free gingival grafts (FGGs)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mucosal excision
Number of subjects: 28
Study: 35619119

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 40
Study: 34066720

Group type: EXPERIMENTAL
Intervention: Active School Travel (AST) promotion through behaviour change frameworks
Number of subjects: 145
Study: 32546249

Group type: EXPERIMENTAL
Intervention: Higher educational level
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Educational level and residence zone interaction
Number of subjects: 244
Study: 35353352

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34044563

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 20 mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 30 mL
Number of subjects: 60
Study: 35131096

Group type: EXPERIMENTAL
Intervention: i.v. olcegepant (n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vehicle control (n=8)
Number of subjects: 16
Study: 35123662

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (anastrozole, exemestane, or letrozole)
Number of subjects: 7030

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 7030
Study: 32782219

Group type: EXPERIMENTAL
Intervention: Ultrasound-based radiomic nomogram
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Radiomic nomogram
Number of subjects: 886
Study: 36413167

Group type: EXPERIMENTAL
Intervention: 3D-printed model preoperative planning
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine preoperative planning
Number of subjects: 20
Study: 36008554

Group type: EXPERIMENTAL
Intervention: Self-sampling HPV test
Number of subjects: 7340
Study: 34020886

Group type: EXPERIMENTAL
Intervention: Pre-cooling (CWI: 30 min of cold water immersion at 22 °C)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pre-cooling combined with per-cooling (PRE + PER)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Warm-up per-cooling (PER: neck-cooling collar applied during the preload)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No-cooling (CON)
Number of subjects: 9
Study: 32820083

Group type: EXPERIMENTAL
Intervention: GOLD (FEV1/FVC <0.70)
Number of subjects: 108246

Group type: EXPERIMENTAL
Intervention: GLI (FEV1/FVC <LLN)
Number of subjects: 108246

Group type: EXPERIMENTAL
Intervention: NHANES (FEV1/FVC <LLN)
Number of subjects: 108246

Group type: EXPERIMENTAL
Intervention: ECSC (FEV1/FVC <LLN)
Number of subjects: 108246

Group type: EXPERIMENTAL
Intervention: CCHS/CGPS (FEV1/FVC <LLN)
Number of subjects: 108246
Study: 34854538

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 49) where the treating team was provided with a summary of family psychosocial risk, measured by the Psychosocial Assessment Tool (PAT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Care as usual control group (n = 44)
Number of subjects: 93
Study: 35770520

Group type: EXPERIMENTAL
Intervention: Mazindol (1 mg, twice a day for 6 months)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mazindol-metformin (500 mg metformin combined with 1 mg mazindol, twice a day for 6 months)
Number of subjects: 137
Study: 33051828

Group type: EXPERIMENTAL
Intervention: Patient ambassador support for 12 weeks
Number of subjects: 36
Study: 35099400

Group type: EXPERIMENTAL
Intervention: MyPlan 2.0 intervention
Number of subjects: 473
Study: 33074074

Group type: EXPERIMENTAL
Intervention: 1 × 10^6 conidia/ml suspension of Colletotrichum siamense
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (non-inoculated Zinnia plants)
Number of subjects: 20
Study: 36208293

Group type: EXPERIMENTAL
Intervention: Belimumab (10 mg/kg intravenous)
Number of subjects: 677

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 677